Form 4 for NRXP NRX Pharmaceuticals, Inc.
Accepted 2022-11-21 00:00:00 ET · period of report 2022-10-21 · accession 0000950142-22-003233 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2022-11-21 | 2022-11-16+ | NRXP | Hurvitz Chaim | Dir | P - Purchase | $1.03 | +500.0K | 459.6K | New | +$514.9K |
| D | 2022-11-21 | 2022-10-21 | NRXP | Hurvitz Chaim | Dir | A - Grant | — | +162.7K | 381.1K | +74% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-11-16 | P | A | 287,812 | $0.99 | 287,812 | D | — | — | (F1) The price reported above reflects the weighted average purchase price per share of common stock (the "Common Stock"), of NRx Pharmaceuticals, Inc. (the "Issuer"). The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2022-11-18 | P | A | 40,408 | $1.10 | 500,000 | D | — | — | (F3) The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common |
| 3 | Common | Common Stock | 2022-11-17 | P | A | 171,780 | $1.08 | 459,592 | D | — | — | (F2) The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected. |
| 4 | Derivative | Employee Stock Option | 2022-10-21 | A | A | 162,660 | — | 381,083 | D | $0.75 · — to 2032-10-21 | 162,660 Common Stock | (F4) Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for the Issuer. |